9II Stock Chart & Stats
€0.03
<€0.01(3.03%)
At close: 4:00 PM EDT
€0.03
<€0.01(3.03%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.04
Previous CloseN/A
Volume0.00
Average Volume (3M)666.00
Market Cap
€7.71M
Enterprise Value€100.39M
Total Cash (Recent Filing)€51.59M
Total Debt (Recent Filing)€6.02M
Price to Earnings (P/E)―
Beta9.76
Next Earnings
Dec 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding277,487,200
10 Day Avg. Volume0
30 Day Avg. Volume666
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.95
Price to Sales (P/S)6.14
P/FCF Ratio-1.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)€2.31M
Bulls Say, Bears Say
Bulls Say
Improving Revenue TractionRevenue reaching approximately 14.8M TTM with reported growth indicates improving commercial traction for DiviTum. If sustained, broader customer use can build operating scale and establish a stronger base for future monetization, even though profitability remains weak.
Low Financial LeverageVery low leverage gives Biovica greater financial flexibility than a heavily indebted development-stage biotech. Limited debt exposure reduces pressure from required debt servicing and leaves more balance-sheet capacity to support product development and commercialization efforts.
Narrowing LossesThe reduction in net losses suggests some progress in controlling the gap between expenses and revenue. Continued improvement could extend the company’s funding runway and move the business closer to a sustainable operating model, provided revenue growth persists.
Bears Say
Negative Gross Profit And Deep LossesNegative gross profit shows that current revenue does not yet cover the direct cost base, while deeply negative operating and net margins indicate substantial additional expenses. This weak economics profile makes sustainable profitability dependent on major improvement in scale or costs.
Substantial Cash BurnPersistent operating and free-cash-flow deficits mean the business is consuming cash rather than funding itself through operations. Although burn improved from roughly -115M in 2024, the remaining outflow can constrain investment capacity and increase reliance on available capital.
Declining Equity And Funding DependenceThe decline in equity reflects the cumulative impact of ongoing losses and reduces the financial cushion supporting operations. Combined with continued cash burn, this indicates dependence on the existing balance sheet and potentially future capital to sustain development and commercialization.
Biovica International AB Class B News
9II FAQ
What was Biovica International AB Class B’s price range in the past 12 months?
Biovica International AB Class B lowest stock price was <€0.01 and its highest was €0.04 in the past 12 months.
What is Biovica International AB Class B’s market cap?
Biovica International AB Class B’s market cap is €7.71M.
When is Biovica International AB Class B’s upcoming earnings report date?
Biovica International AB Class B’s upcoming earnings report date is Dec 17, 2026 which is in 52 days.
How were Biovica International AB Class B’s earnings last quarter?
Biovica International AB Class B released its earnings results on Sep 09, 2026. The company reported -€0.006 earnings per share for the quarter.
Is Biovica International AB Class B overvalued?
According to Wall Street analysts Biovica International AB Class B’s price is currently Overvalued.
Does Biovica International AB Class B pay dividends?
Biovica International AB Class B does not currently pay dividends.
What is Biovica International AB Class B’s EPS estimate?
Biovica International AB Class B’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biovica International AB Class B have?
Biovica International AB Class B has 277,487,200 shares outstanding.
What happened to Biovica International AB Class B’s price movement after its last earnings report?
Biovica International AB Class B reported an EPS of -€0.006 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Biovica International AB Class B?
Currently, no hedge funds are holding shares in DE:9II
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biovica International AB Class B
Biovica International AB (publ) operates as a biotechnology enterprise, concentrating on the development and market introduction of sophisticated blood-based biomarker tests. These diagnostic solutions aim to enhance the tracking and prediction of cancer treatment efficacy across Sweden and globally, with a significant focus on breast cancer. A key offering is DiviTum, a biomarker assay engineered to measure the activity levels of the enzyme thymidine kinase-1 within blood serum or cell cultures. The company's clientele includes oncology research centers, pharmaceutical corporations, and various collaborative organizations. Established in 2008, Biovica's main office is situated in Uppsala, Sweden.
Technical Analysis
Elicera Therapeutics AB
―
Spago Nanomedical AB
―
Cantargia AB
―
Sprint Bioscience AB
―
Fluicell AB
―